Current Pharmaceutical Design - Volume 7, Issue 3, 2001

Leukotriene A 4 (LTA4 ) hydrolase is a zinc containing enzyme which stereospecifically catalyzes the hydrolysis of the epoxide LTA 4 to the diol leukotriene B 4 (LTB4 ). There is substantial evidence that LTB 4 plays a significant role in the amplification of many inflammatory disease states. Therapeutic agents which selectively inhibit LTA4 hydrolase would block the formation of LTB4 and thus be potentially useful for the treat Read More

Recent progress in the development of inhibitors of human Type II s PLA2 as potential anti inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY 315920 (S 5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY 315920 is ex Read More

Sub acute and chronic bronchitis (SACB) are among the least well studied major medical problems that exist today. While much research and novel drug discovery have focused on asthma, comparatively little has been performed on chronic bronchitis, the fourth or fifth most frequent disease (4 to 6 percent of the population over 45 years of age), or on sub acute bronchitis, the persistent symptoms of a respiratory infection whic Read More

Alopecia areata is considered to be a T cell mediated autoimmune disease of the hair follicle. Current immunosuppressive approaches and immunomodulatory treatment with contact sensitizers such as diphenylcyclopropenone and squaric acid dibutylester are dealt with in this review article. The efficacy of the various modes of treatment is evaluated by a review of literature and their mode of action is discussed. In ac Read More